A severe acute respiratory syndrome coronavirus 2 (SARS CoV2), also known as coronavirus disease 2019 , is an ongoing pandemic. Although COVID-19 is primarily a lung disease, it has been linked to several cutaneous symptoms in COVID-19 patients. 1 The reactivation of the varicella-zoster virus (VZV), which causes herpes zoster, is a noteworthy discovery (HZ). 1 HZ was the first sign of COVID-19 infection in several patients. Vaccination initiatives against COVID-19 have been carried over since December 2020. Pain at the injection site, fever, nausea, myalgia, and exhaustion are among the most commonly reported side effects. 2 HZ was noted in patients after vaccination with tozinameran, Pfizer-BNT162b2 mRNA, Moderna mRNA-1273, and ChAdOx1 nCoV-19. [3][4][5] However, reactivation of HZ has not been reported so far. Here, we describe a rare side effect, that is, HZ eruptions in 51-year-old male patient after vaccination with Sinopharm (Vero cell). | CASE PRESENTATIONA 51-year-old male patient presented to our center with the chief complaints of rashes over the abdomen (T 8 -T 10 dermatome distribution) for five days (Figure 1). The rashes were itchy, and the tender lesions spread along the periumbilical region. He complained of a burning sensation over the lesions. He had no history of fever, limb weakness, or paresthesia. He does not smoke or consume alcohol. He had herpes zoster infection at 3 years of age on trunk, which he recalls as vesicular eruptions which subsided without treatment. He had no history of hypertension, diabetes mellitus, previous COVID-19 infection, and pulmonary tuberculosis. He was administered Sinopharm BBIBP-CorV (Vero cell) COVID-19 vaccine five days prior to the cutaneous reaction.On examination of the lesion, the distribution was over dermatome T 8 -T 10 in the right side of back and abdomen. Rashes were maculopapular, vesicular, pustular with crusts, and tender to touch, and spread over an area

Introduction The post-coronavirus disease 2019 (COVID-19) syndrome is defined as the persistence of symptoms after viral clearance and the emergence of new symptoms after a few months following recovery from COVID-19. This study aimed to assess the prevalence of post-COVID-19 syndrome and the risk factors that contribute to its development. Methods This study was conducted prospectively in Tribhuvan University Teaching Hospital (TUTH), located in Maharajgunj, Kathmandu. The patients were followed up for three months. Results The post-COVID status of 300 patients admitted to the COVID emergency of TUTH was studied. The mean age of the patients was 46.6±15.7 years, and the proportion of male (56%) was slightly higher than female (44%). Most of the patients (81.7%) had fever on their presentation to the emergency which was followed by fatigue (81.3%) and cough (78.3%). During the post-COVID phase, fatigue was the most common persistent symptom, with 34% experiencing fatigue after 60 days and 28.3% even after 90 days from the onset of symptoms. Univariate logistic regression showed sore throat (OR 4.6; 95% CI (2.8–7.6)), rhinitis (OR 3.6; 95% CI (2.1–5.9)), fatigue (OR 3.7; 95% CI (1.8–7.6)), diarrhea (OR 4.1; 95% CI (2.4–6.9)), anosmia (OR 6.7; 95% CI (3.9–11.3)), ageusia (OR 7.8; 95% CI (4.5–13.4)) and shortness of breath (OR 14.9; 95% CI (1.8–119.6)) at admission were all predictors of post-COVID syndrome after three months. Conclusion Even after recovering from COVID-19, people with COVID-19 may develop symptoms. As a result, COVID-19’s long-term consequences should not be neglected, as they may lead to increased morbidity among patients, consumption of financial resources, and added burden on the health system.

This case demonstrates pneumothorax as a consequence of COVID‐19 and emphasizes the significance of follow‐up of the COVID‐19 patients.

No abstract

Introduction: Pegcetacoplan, a pegylated penta-decapeptide, targets complement C3 to control both intravascular and extravascular hemolysis. This systematic review aims to study the efficacy and safety of pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH). Methods:We performed a comprehensive and systematic literature search for all studies on PubMed, Google Scholar, Cochrane Library, and clini caltr ials.gov. The studies were searched using keywords "paroxysmal nocturnal hemoglobinuria" or "PNH," "Pegcetacoplan" or "Empaveli." The primary outcomes included change in hemoglobin level, transfusion independence, absolute reticulocyte count, and lactate dehydrogenase (LDH) level after pegcetacoplan therapy. The safety outcomes included the proportion of deaths and adverse effects. Results:We included a total of three studies. The total number of patients with PNH was112. 59.83% were female. In the PADDOCK study and study by Hillmen et al., the average increase in hemoglobin was 3.68 g/L and 2.37 g/L, respectively. In the study by de Castro et al., the hemoglobin level increased from below the lower limit of normal and stayed in the normal range (11.1-15.9 g/L). Absolute reticulocyte count and LDH levels decreased in all patients receiving pegcetacoplan. In the study by de Castro et al., LDH level remained stable, and within <1.5× upper limit of normal, whereas in the study by Hillman, the mean change of LDH from baseline was −15 ± 43 U/L. Two of six, seven of 23, and seven of 41 patients reported adverse events in the study by de Castro et al., PADDOCK, and Hillmen et al., respectively. Conclusion:Pegcetacoplan effectively improves hemoglobin level and transfusion requirements in patients with PNH, including those unresponsive to eculizumab.